Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05330104 · ClinicalTrials.gov registry record · NA

SENSE Study: Remote Symptom Monitoring for Patients With Chemotherapy-induced Peripheral Neuropathy

A NA study, sponsored by Allina Health System.

Completed
Registry status
NA
Development phase
12
Enrollment target

NCT05330104 is a NA study that has completed, run by Allina Health System. The registered enrollment target is 12 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05330104, a NA study, has completed, sponsored by Allina Health System.

COMPLETED
Registry status
NA
Development phase
12 participants
Enrollment target

Study Summary

The main purpose of this study is to determine the threshold level of lower extremity CIPN symptoms that put patients who have been prescribed a neurotoxic chemotherapy agent (e.g., paclitaxel, docetaxel, oxaliplatin or cisplatin) as part of their treatment regimen for cancer at-risk for falling. The investigators believe that by specifying early CIPN symptoms that predict fall-risk, The investigators will ultimately be able to identify at-risk patients who could be referred to rehabilitative services to prevent injurious falls while enabling them to continue the chemotherapy treatment that could save their lives.

Interventions

  • BEHAVIORAL Mobile Ecological Momentary Assessment

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2022-01-03
Est. Completion 2025-06-16
Phase NA

Sponsor

Allina Health System

32 total trials

What the Registry Record Tells You About NCT05330104

The ClinicalTrials.gov registry entry for NCT05330104 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allina Health System, which has 32 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Mobile Ecological Momentary Assessment is the first listed.

NCT05330104 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05330104 about?

NCT05330104 is a clinical study titled "SENSE Study: Remote Symptom Monitoring for Patients With Chemotherapy-induced Peripheral Neuropathy". The main purpose of this study is to determine the threshold level of lower extremity CIPN symptoms that put patients who have been prescribed a neurotoxic chemotherapy agent (e.g., paclitaxel, docetaxel, oxaliplatin or cisplatin) as part of their treatment regimen for cancer at-risk for falling. Th...

What is the current status of trial NCT05330104?

This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2022-01-03. Estimated completion is 2025-06-16.

What interventions are being tested in trial NCT05330104?

The interventions under investigation include: Mobile Ecological Momentary Assessment (BEHAVIORAL).

Who is sponsoring clinical trial NCT05330104?

This trial is sponsored by Allina Health System, which has 32 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.